COVID-19 in ocrelizumab-treated people with multiple sclerosis

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China

(2020) Zunyou Wu et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

SARS‐CoV ‐2 and Multiple Sclerosis: Not All Immune Depleting DMTs are Equal or Bad

(2020) Sandra Amor et al.   ANNALS OF NEUROLOGY

Immunology of COVID-19: current state of the science

(2020) Nicolas Vabret et al.   IMMUNITY

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

(2020) Safiya Richardson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal

(2020) Hasan K. Siddiqi et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

COVID-19: consider cytokine storm syndromes and immunosuppression

(2020) Puja Mehta et al.   LANCET

Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic

(2020) Lorenzo D’Antiga   LIVER TRANSPLANTATION

Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic

(2020) Wallace Brownlee et al.   NEUROLOGY

Two X‐linked agammaglobulinemia patients develop pneumonia as COVID‐19 manifestation but recover

(2020) Annarosa Soresina et al.   PEDIATRIC ALLERGY AND IMMUNOLOGY

Estimating the burden of SARS-CoV-2 in France

(2020) Henrik Salje et al.   SCIENCE

The COVID-19 pandemic and the use of MS disease-modifying therapies

(2020) Gavin Giovannoni et al.   Multiple Sclerosis and Related Disorders

COVID‐19 vaccine‐readiness for anti‐CD20‐depleting therapy in autoimmune diseases

(2020) D. Baker et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination

(2020) Crystal Zheng et al.   CNS DRUGS

COVID-19 in multiple sclerosis: The Dutch experience

(2020) Floor C Loonstra et al.   Multiple Sclerosis Journal

COVID-19 in people with multiple sclerosis: A global data sharing initiative

(2020) Liesbet M Peeters et al.   Multiple Sclerosis Journal

Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient

(2020) Hannah Wurm et al.   Multiple Sclerosis Journal

Factors associated with COVID-19-related death using OpenSAFELY

(2020) Elizabeth J. Williamson et al.   NATURE

Neurological immunotherapy in the era of COVID-19 — looking for consensus in the literature

(2020) Catharina Korsukewitz et al.   Nature Reviews Neurology

Are patients with multiple sclerosis (MS) at higher risk of COVID-19 infection?

(2020) Mahsa Ghajarzadeh et al.   NEUROLOGICAL SCIENCES

Five-years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension

(2020) Stephen L. Hauser et al.   NEUROLOGY

Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study

(2020) Amit Bar-Or et al.   NEUROLOGY

Vaccination in B-cell depleted MS patients

(2020) Joep Killestein et al.   NEUROLOGY

Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis

(2020) Céline Louapre et al.   JAMA Neurology

Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study

(2020) Andrew Clark et al.   Lancet Global Health

Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab

(2020) Kulachanya Suwanwongse et al.   Multiple Sclerosis and Related Disorders

Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19

(2020) Gavin Giovannoni   Multiple Sclerosis and Related Disorders

The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic

(2020) David Baker et al.   Multiple Sclerosis and Related Disorders

B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran

(2020) Farinaz Safavi et al.   Multiple Sclerosis and Related Disorders

Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic

(2020) Mahsa Ghajarzadeh et al.   Multiple Sclerosis and Related Disorders

Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, Spain

(2020) Paloma Montero-Escribano et al.   Multiple Sclerosis and Related Disorders

COVID-19 in persons with multiple sclerosis treated with ocrelizumab – A pharmacovigilance case series

(2020) Richard Hughes et al.   Multiple Sclerosis and Related Disorders

COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?

(2020) Giovanni Novi et al.   Multiple Sclerosis and Related Disorders

Managing Disease-Modifying Therapies and Breakthrough Activity in Multiple Sclerosis Patients During the COVID-19 Pandemic: Toward an Optimized Approach

(2020) Sherif M Hamdy et al.   Therapeutics and Clinical Risk Management

COVID-19 outcomes in MS

(2020) Erica Parrotta et al.   Neurology-Neuroimmunology & Neuroinflammation

Population-level COVID-19 mortality risk for non-elderly individuals overall and for non-elderly individuals without underlying diseases in pandemic epicenters

(2020) John P.A. Ioannidis et al.   ENVIRONMENTAL RESEARCH

Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins

(2020) José María Díez et al.   Immunotherapy

Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China

(2020) Fan Wu et al.   JAMA Internal Medicine

COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies

(2020) Virginia Meca-Lallana et al.   Multiple Sclerosis and Related Disorders

Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia

(2020) William L Conte   Multiple Sclerosis and Related Disorders

Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report

(2020) Matteo Lucchini et al.   Multiple Sclerosis and Related Disorders

Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab

(2020) Jeanine Rempe Thornton et al.   Multiple Sclerosis and Related Disorders

Factors Associated with Prescribing Oral Disease Modifying Agents in Multiple Sclerosis: a Real-world Analysis of Electronic Medical Records

(2020) Jagadeswara R. Earla et al.   Multiple Sclerosis and Related Disorders

Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab

(2020) Marco Iannetta et al.   Multiple Sclerosis and Related Disorders

Validation of an algorithm for identifying MS cases in administrative health claims datasets

(2019) William J. Culpepper et al.   NEUROLOGY

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

(2017) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

(2017) Xavier Montalban et al.   NEW ENGLAND JOURNAL OF MEDICINE